FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114061161> ?p ?o ?g. }

• W2114061161 endingPage "1251" @default.
• W2114061161 startingPage "1246" @default.
• W2114061161 abstract "ABSTRACT This study evaluated the safety, tolerability, and pharmacokinetics of a posaconazole i.v. (intravenous) solution. This was a single-center, 2-part, randomized, rising single- and multiple-dose study in healthy adults. In part 1, subjects received 0 (vehicle), 50, 100, 200, 250, or 300 mg posaconazole in a single dose i.v. by 30-min peripheral infusion (6 cohorts of 12 subjects each [9 active and 3 placebo], making a total of 72 subjects). Blood samples were collected until 168 h postdose. In part 2, subjects were to receive 2 peripheral infusions at a 12-h interval on day 1 followed by once-daily infusion for 9 days. However, part 2 was terminated early because of high rates of infusion site reactions with multiple dosing at the same infusion site. The pharmacokinetics results for part 1 ( n = 45 subjects) showed that the mean posaconazole exposure (area under the concentration-time curve from time zero to infinity [AUC 0–∞ ]) ranged from 4,890 to 46,400 ng · h/ml (range of coefficient of variation values, 26 to 50). The dose-proportionality slope estimate (90% confidence interval) for AUC 0–∞ was 1.30 (1.19 to 1.41), indicating a greater-than-dose-proportional increase. The data for safety in part 1 show that 29/72 subjects had ≥1 adverse event. Infusion site reactions were reported in 2/9 vehicle subjects, 0/18 placebo subjects, and 7/45 i.v. posaconazole subjects. The data for safety in part 2 show that infusion site reactions were reported in 1/4 (25%) placebo subjects, 3/9 (33%) vehicle control subjects, and 4/5 (80%) i.v. posaconazole (100 mg) subjects (3 posaconazole recipients subsequently developed thrombophlebitis and were discontinued from treatment). In conclusion, the posaconazole i.v. solution showed a greater-than-dose-proportional increase in exposure, primarily at doses below 200 mg. When administered peripherally at the same infusion site, multiple dosing of i.v. posaconazole led to unacceptably high rates of infusion site reactions. Intravenous posaconazole was otherwise well tolerated. Single doses of i.v. posaconazole were tolerated when given through a peripheral vein over 30 min." @default.
• W2114061161 created "2016-06-24" @default.
• W2114061161 creator A5008561024 @default.
• W2114061161 creator A5011421448 @default.
• W2114061161 creator A5028016060 @default.
• W2114061161 creator A5034764399 @default.
• W2114061161 creator A5044184353 @default.
• W2114061161 creator A5045339175 @default.
• W2114061161 creator A5056653642 @default.
• W2114061161 date "2015-02-01" @default.
• W2114061161 modified "2023-10-14" @default.
• W2114061161 title "Pharmacokinetics and Safety Study of Posaconazole Intravenous Solution Administered Peripherally to Healthy Subjects" @default.
• W2114061161 cites W1736726786 @default.
• W2114061161 cites W1988385266 @default.
• W2114061161 cites W1989345554 @default.
• W2114061161 cites W1995377218 @default.
• W2114061161 cites W2032771458 @default.
• W2114061161 cites W2041707596 @default.
• W2114061161 cites W2106243271 @default.
• W2114061161 cites W2117813373 @default.
• W2114061161 cites W2119544769 @default.
• W2114061161 cites W2162626697 @default.
• W2114061161 cites W2418920851 @default.
• W2114061161 cites W3187645783 @default.
• W2114061161 doi "https://doi.org/10.1128/aac.04223-14" @default.
• W2114061161 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4335848" @default.
• W2114061161 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25512407" @default.
• W2114061161 hasPublicationYear "2015" @default.
• W2114061161 type Work @default.
• W2114061161 sameAs 2114061161 @default.
• W2114061161 citedByCount "47" @default.
• W2114061161 countsByYear W21140611612015 @default.
• W2114061161 countsByYear W21140611612016 @default.
• W2114061161 countsByYear W21140611612017 @default.
• W2114061161 countsByYear W21140611612018 @default.
• W2114061161 countsByYear W21140611612019 @default.
• W2114061161 countsByYear W21140611612020 @default.
• W2114061161 countsByYear W21140611612021 @default.
• W2114061161 countsByYear W21140611612022 @default.
• W2114061161 countsByYear W21140611612023 @default.
• W2114061161 crossrefType "journal-article" @default.
• W2114061161 hasAuthorship W2114061161A5008561024 @default.
• W2114061161 hasAuthorship W2114061161A5011421448 @default.
• W2114061161 hasAuthorship W2114061161A5028016060 @default.
• W2114061161 hasAuthorship W2114061161A5034764399 @default.
• W2114061161 hasAuthorship W2114061161A5044184353 @default.
• W2114061161 hasAuthorship W2114061161A5045339175 @default.
• W2114061161 hasAuthorship W2114061161A5056653642 @default.
• W2114061161 hasBestOaLocation W21140611611 @default.
• W2114061161 hasConcept C111113717 @default.
• W2114061161 hasConcept C112705442 @default.
• W2114061161 hasConcept C126322002 @default.
• W2114061161 hasConcept C126894567 @default.
• W2114061161 hasConcept C142724271 @default.
• W2114061161 hasConcept C16005928 @default.
• W2114061161 hasConcept C197934379 @default.
• W2114061161 hasConcept C204787440 @default.
• W2114061161 hasConcept C27081682 @default.
• W2114061161 hasConcept C2776768635 @default.
• W2114061161 hasConcept C2777071850 @default.
• W2114061161 hasConcept C2777288759 @default.
• W2114061161 hasConcept C2778375690 @default.
• W2114061161 hasConcept C2778566413 @default.
• W2114061161 hasConcept C2779548794 @default.
• W2114061161 hasConcept C42219234 @default.
• W2114061161 hasConcept C44249647 @default.
• W2114061161 hasConcept C6557445 @default.
• W2114061161 hasConcept C71924100 @default.
• W2114061161 hasConcept C76318530 @default.
• W2114061161 hasConcept C86803240 @default.
• W2114061161 hasConcept C87813604 @default.
• W2114061161 hasConcept C98274493 @default.
• W2114061161 hasConceptScore W2114061161C111113717 @default.
• W2114061161 hasConceptScore W2114061161C112705442 @default.
• W2114061161 hasConceptScore W2114061161C126322002 @default.
• W2114061161 hasConceptScore W2114061161C126894567 @default.
• W2114061161 hasConceptScore W2114061161C142724271 @default.
• W2114061161 hasConceptScore W2114061161C16005928 @default.
• W2114061161 hasConceptScore W2114061161C197934379 @default.
• W2114061161 hasConceptScore W2114061161C204787440 @default.
• W2114061161 hasConceptScore W2114061161C27081682 @default.
• W2114061161 hasConceptScore W2114061161C2776768635 @default.
• W2114061161 hasConceptScore W2114061161C2777071850 @default.
• W2114061161 hasConceptScore W2114061161C2777288759 @default.
• W2114061161 hasConceptScore W2114061161C2778375690 @default.
• W2114061161 hasConceptScore W2114061161C2778566413 @default.
• W2114061161 hasConceptScore W2114061161C2779548794 @default.
• W2114061161 hasConceptScore W2114061161C42219234 @default.
• W2114061161 hasConceptScore W2114061161C44249647 @default.
• W2114061161 hasConceptScore W2114061161C6557445 @default.
• W2114061161 hasConceptScore W2114061161C71924100 @default.
• W2114061161 hasConceptScore W2114061161C76318530 @default.
• W2114061161 hasConceptScore W2114061161C86803240 @default.
• W2114061161 hasConceptScore W2114061161C87813604 @default.
• W2114061161 hasConceptScore W2114061161C98274493 @default.
• W2114061161 hasIssue "2" @default.
• W2114061161 hasLocation W21140611611 @default.
• W2114061161 hasLocation W21140611612 @default.

• next